Insulin Lispro 25% + Insulin Lispro Protamine 75%

Insulin Lispro 25% + Insulin Lispro Protamine 75% is a premixed insulin analogue formulation containing 25% rapid-acting insulin lispro and 75% intermediate-acting insulin lispro protamine suspension. It is used to improve blood glucose control in people with diabetes who require both mealtime and longer-lasting insulin activity. Insulin lispro is a modified form of human insulin that is absorbed rapidly after subcutaneous injection, helping control the rise in blood glucose associated with meals. Insulin lispro protamine combines insulin lispro with protamine to slow its absorption and extend its glucose-lowering effect. Both components act through insulin receptors, promoting glucose uptake by muscle and fat cells and reducing glucose production by the liver. The formulation is administered by subcutaneous injection, with timing determined by the specific product instructions. Because both components are supplied in a fixed ratio, the rapid-acting and intermediate-acting doses cannot be adjusted independently. This may simplify treatment for some patients but requires a consistent meal routine, appropriate food intake, and regular blood glucose monitoring. The dose and schedule must be individualised according to glucose readings, diabetes treatment history, physical activity, meal patterns, and clinical response. Correct administration and recognition of hypoglycaemia are essential for safe use.

Insulin lispro was developed using recombinant DNA technology to provide a rapid-acting insulin analogue with faster absorption than regular human insulin. Combining insulin lispro with insulin lispro protamine created premixed formulations that provide both rapid and intermediate insulin activity in a fixed proportion. The 25% insulin lispro and 75% insulin lispro protamine formulation is marketed in Europe as Humalog Mix25. The European Medicines Agency assessed the Humalog range, including premixed formulations, for the treatment of diabetes mellitus. In the United States, the related formulation Humalog Mix75/25, containing 25% insulin lispro and 75% insulin lispro protamine, received FDA approval in 1999. Product names differ between regions because some use the percentage of rapid-acting insulin first, while others identify the percentage of intermediate-acting insulin first. Clinical studies of insulin lispro and premixed formulations assessed blood glucose control and safety in people with diabetes. Approval status, age eligibility, dosing instructions, and available presentations may vary by country and product; the locally approved prescribing information should be followed.

Insulin Lispro 25% + Insulin Lispro Protamine 75% is used to improve blood glucose control in people with diabetes mellitus who require a combination of rapid-acting and intermediate-acting insulin. It may be prescribed for adults with type 1 or type 2 diabetes when a premixed insulin regimen is considered appropriate, subject to the specific product's approved indication. In type 1 diabetes, it may form part of an individualised insulin regimen, although some patients require more flexible separate basal and mealtime insulin dosing. In type 2 diabetes, it may be used when other glucose-lowering treatments do not adequately control blood glucose or when insulin therapy is otherwise clinically indicated. The fixed ratio is intended to provide both mealtime and longer-lasting insulin activity, but it does not allow each component to be adjusted separately. It is not intended for the treatment of diabetic ketoacidosis.

Insulin Lispro 25% + Insulin Lispro Protamine 75% is administered by subcutaneous injection, commonly into the abdomen, thigh, upper arm, or buttocks, according to the specific product instructions. Humalog Mix25 is generally administered shortly before a meal; the US-labelled equivalent Humalog Mix75/25 is administered within 15 minutes before a meal. The exact timing must follow the locally approved product information. The dose is individualised according to glucose readings, previous insulin use, meal patterns, physical activity, and treatment goals. Some regimens use two injections daily, but the appropriate schedule must be determined by the treating clinician. The suspension must be resuspended as instructed before injection. It must not be administered intravenously or through an insulin pump. Because the two components are supplied in a fixed ratio, they cannot be titrated independently. Regular glucose monitoring and supervised dose adjustments are necessary.

The most important common side effect is hypoglycaemia, or low blood glucose. Symptoms may include sweating, trembling, hunger, dizziness, headache, confusion, and a rapid heartbeat. Other possible effects include weight gain, injection-site redness, itching, swelling or discomfort, and changes in the fatty tissue beneath the skin, including thickening or indentations when injection sites are repeatedly used. Temporary swelling may also occur. Hypoglycaemia risk can increase if meals are missed or delayed, physical activity changes unexpectedly, alcohol is consumed, or the prescribed dose exceeds the body's needs. Side effects vary between individuals and may be influenced by kidney or liver function and other medicines. Patients should learn to recognise and manage low blood glucose and discuss recurring symptoms or persistent injection-site reactions with their healthcare professional.

Severe hypoglycaemia can cause seizures, loss of consciousness, injury, or other life-threatening complications and requires urgent treatment. Serious allergic reactions, including anaphylaxis, are possible but uncommon. Insulin can also cause low blood potassium levels, which may be dangerous in susceptible patients. Incorrect dosing, inappropriate meal timing, or interruption of insulin treatment can lead to significant glucose disturbances; inadequate insulin in people with type 1 diabetes can result in diabetic ketoacidosis. The formulation must not be used during an episode of hypoglycaemia or by people with a known serious hypersensitivity to the product or its ingredients. Its fixed ratio may make it unsuitable for patients who need independent adjustment of mealtime and longer-acting insulin. Treatment should not be stopped or changed without medical guidance. Insulin pens, cartridges, needles, and syringes must not be shared between patients.

Insulin requirements can change with kidney or liver impairment, older age, pregnancy, illness, changes in body weight, diet, or physical activity. Other glucose-lowering medicines may increase the risk of hypoglycaemia, while corticosteroids, some diuretics, thyroid hormones, and certain other medicines may increase blood glucose or alter insulin requirements. Beta-blockers may mask some warning signs of hypoglycaemia, and alcohol can increase or prolong its risk. Patients should inform their healthcare professional about all prescription medicines, non-prescription products, and supplements they use. Regular meal timing and appropriate carbohydrate intake are particularly important with premixed insulin because its two components cannot be adjusted separately. Injection sites should be rotated, and the suspension should be stored according to product-specific instructions and protected from freezing and excessive heat. Patients should not change insulin products, concentrations, or delivery devices without professional advice.

Before prescribing this formulation, assess the patient's diabetes type, blood glucose profile, meal routine, previous insulin regimen, hypoglycaemia risk, kidney and liver function, and ability to use the injection device safely. Confirm the exact product name and ratio because Humalog Mix25 and Humalog Mix75/25 use different naming conventions despite containing the same proportions of rapid-acting and intermediate-acting components. Explain the importance of meal timing, consistent food intake, glucose monitoring, correct resuspension, injection-site rotation, and proper storage. Ensure patients know how to recognise and manage hypoglycaemia and when to seek urgent medical assistance. Review glucose records after treatment initiation or dose changes and reassess the regimen when diet, activity, illness, pregnancy, or interacting medicines change. Consider whether the fixed ratio provides sufficient flexibility for the patient's daily routine and glucose pattern. Pharmacists should verify the prescribed formulation, concentration, and delivery device before dispensing.